<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Vis</journal-id><journal-id journal-id-type="publisher-id">MV</journal-id><journal-title>Molecular Vision</journal-title><issn pub-type="epub">1090-0535</issn><publisher><publisher-name>Molecular Vision</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">148</article-id><article-id pub-id-type="publisher-id">2008MOLVIS0114</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>&#x000ad;Exfoliation syndrome and exfoliation glaucoma-associated <italic>LOXL1</italic> variations are not involved in pigment dispersion syndrome and pigmentary glaucoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rao</surname><given-names>Kollu Nageswara</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ritch</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dorairaj</surname><given-names>Syril K.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kaur</surname><given-names>Inderjeet</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Liebmann</surname><given-names>Jeffrey M.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Thomas</surname><given-names>Ravi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Chakrabarti</surname><given-names>Subhabrata</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><aff id="aff1"><label>1</label>Hyderabad Eye Research Foundation, L.V. Prasad Eye Institute, Hyderabad, India</aff><aff id="aff2"><label>2</label>Einhorn Clinical Research Center, New York Eye and Ear Infirmary, New York, NY</aff><aff id="aff3"><label>3</label>Beth Israel Medical Center, New York, NY</aff><aff id="aff4"><label>4</label>Queensland Eye Institute, Brisbane, Australia</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to: Dr. Subhabrata Chakrabarti, Kallam Anji Reddy Molecular Genetics Laboratory, Brien Holden Eye Research Centre, L.V. Prasad Eye Institute, Road No. 2, Banjara Hills, Hyderabad, 500034, India; Phone: +91-40-30612524; FAX: +91-40-23548271; email: <email xlink:href="subho@lvpei.org">subho@lvpei.org</email></corresp></author-notes><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>09</day><month>7</month><year>2008</year></pub-date><volume>14</volume><fpage>1254</fpage><lpage>1262</lpage><history><date date-type="received"><day>12</day><month>4</month><year>2008</year></date><date date-type="accepted"><day>26</day><month>6</month><year>2008</year></date></history><permissions><copyright-year>2008</copyright-year><copyright-holder>Molecular Vision</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title>Purpose</title><p>Single nucleotide polymorphisms (SNPs) in the <italic>LOXL1</italic> gene have been implicated in exfoliation syndrome (XFS) and exfoliation glaucoma (XFG). We have shown that these SNPs are not associated with the primary glaucomas such as primary open-angle (POAG) glaucoma and primary angle-closure glaucoma (PACG). To further establish the specificity of <italic>LOXL1</italic> SNPs for XFS and XFG, we determined whether these SNPs were involved in pigment dispersion syndrome (PDS) and pigmentary glaucoma (PG).</p></sec><sec sec-type="methods"><title>Methods</title><p>Three SNPs of <italic>LOXL1</italic> (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1048661">rs1048661</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3825942">rs3825942</ext-link>, and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2165241">rs2165241</ext-link>) were screened in a cohort of 78 unrelated and clinically well characterized glaucoma cases comprising of PG (n=44) and PDS (n=34) patients as well as 108 ethnically matched normal controls of Caucasian origin. The criteria for diagnosis of PDS/PG were Krukenberg spindle, hyperpigmentation of the trabecular meshwork, and wide open angle. Transillumination defects were detected by infrared pupillography, and the presence of a Zentmayer ring was considered as a confirmatory sign. All three SNPs were genotyped in cases and controls by resequencing the genomic region of <italic>LOXL1</italic> harboring these variants and were further confirmed by polymerase chain reaction (PCR)-based restriction digestions. Haplotypes were generated from the genotype data, and the linkage disequilibrium (LD) and haplotype analysis were done with <ext-link ext-link-type="uri" xlink:href="http://www.broad.mit.edu/mpg/haploview">Haploview</ext-link> software that uses the expectation maximization (EM) algorithm.</p></sec><sec><title>Results</title><p>The <italic>LOXL1</italic> SNPs showed no significant association with PDS or PG. There was no significant difference in the frequencies of the risk alleles of <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1048661">rs1048661</ext-link> (&#x02018;G&#x02019; allele; p=0.309), <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3825942">rs3825942</ext-link> (&#x02018;G&#x02019; allele&#x02019; p=0.461), and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2165241">rs2165241</ext-link> (&#x02018;T&#x02019; allele; p=0.432) between PG/PDS cases and controls. Similarly, there was no involvement of the XFS/XFG-associated haplotypes, &#x02018;G-G&#x02019; (p=0.643; [OR=1.08, 95%CI, 0.59&#x02013;1.97]) and &#x02018;T-G&#x02019; (p=0.266; [OR=1.35, 95%CI, 0.70&#x02013;2.60]), with the PDS/PG phenotypes. The risk haplotype &#x02018;G-G&#x02019; was observed in ~55% of the normal controls.</p></sec><sec><title>Conclusions</title><p>There was no involvement of the <italic>LOXL1</italic> SNPs in patients with PDS and PG. The results further indicate that the associations of these SNPs are specific to XFS/XFG.</p></sec></abstract><custom-meta-wrap><custom-meta><meta-name>GalleyStatus</meta-name><meta-value>Export to XML</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Glaucoma is a chronic, progressive neurodegenerative disorder characterized by a specific pattern of optic nerve head and visual field damage, which represents the final common pathway of a heterogeneous group of entities that affect the eye [<xref ref-type="bibr" rid="r1">1</xref>,<xref ref-type="bibr" rid="r2">2</xref>]. It is the second leading cause of irreversible blindness worldwide, and it has been estimated that it will affect approximately 80 million people by the year 2020 [<xref ref-type="bibr" rid="r3">3</xref>].</p><p>Exfoliation syndrome (XFS) is an age-related, generalized disorder of the extracellular matrix characterized by the production and progressive accumulation of a fibrillar extracellular material in many ocular tissues and is the most common identifiable cause of open-angle glaucoma worldwide [<xref ref-type="bibr" rid="r4">4</xref>]. It plays an etiologic role in open-angle glaucoma, angle-closure glaucoma, cataract, and retinal vein occlusion and has been associated with an increasing number of systemic disorders including vascular disease, hearing loss, and Alzheimer disease [<xref ref-type="bibr" rid="r5">5</xref>-<xref ref-type="bibr" rid="r8">8</xref>]. Exfoliation syndrome appears to be a disease of elastic tissue microfibrils.</p><p>Recently, single nucleotide polymorphisms (SNPs) in the <italic>LOXL1</italic> gene (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=153456">OMIM 153456</ext-link>) at 15q24.1 have been implicated in exfoliation syndrome and exfoliation glaucoma (XFG) [<xref ref-type="bibr" rid="r9">9</xref>]. Two non-synonymous SNPs in exon 1 of <italic>LOXL1</italic> (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1048661">rs1048661</ext-link> [R141L] and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3825942">rs3825942</ext-link> [G135D]) were demonstrated to exhibit a strong association with XFS and XFG in an Icelandic and Swedish population [<xref ref-type="bibr" rid="r9">9</xref>] that was later replicated across multiple populations worldwide [<xref ref-type="bibr" rid="r10">10</xref>-<xref ref-type="bibr" rid="r19">19</xref>]. It was also shown that <italic>LOXL1</italic> SNPs are not associated with primary glaucomas [<xref ref-type="bibr" rid="r20">20</xref>,<xref ref-type="bibr" rid="r21">21</xref>].</p><p>Pigment dispersion syndrome (PDS; <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=600510">OMIM 600510</ext-link>) and pigmentary glaucoma (PG) are characterized by a disruption of the iris pigment epithelium (IPE) and deposition of the dispersed pigment granules throughout the anterior segment [<xref ref-type="bibr" rid="r22">22</xref>]. The classic diagnostic triad consists of corneal pigmentation (Krukenberg spindle); slit-like, radial, mid-peripheral iris transillumination defects; and dense trabecular pigmentation [<xref ref-type="bibr" rid="r23">23</xref>]. The iris insertion is typically posterior, and the peripheral iris tends to bow posteriorly [<xref ref-type="bibr" rid="r24">24</xref>]. About 80% of patients with PDS are myopes and 20% are emmetropes. The basic abnormality in this hereditary disorder remains unknown.</p><p>The frequency with which PDS converts to PG has probably been greatly overestimated. The three studies that have examined patients longitudinally suggest that up to 50% will eventually develop glaucoma [<xref ref-type="bibr" rid="r25">25</xref>-<xref ref-type="bibr" rid="r27">27</xref>]. However, the true rate of PDS in the general population may be an order of magnitude greater than has previously been suspected [<xref ref-type="bibr" rid="r28">28</xref>]. In a retrospective community-based study, 113 patients of whom nine developed PG or elevated intraocular pressure (IOP) that required therapy were newly diagnosed with PDS over 24 years [<xref ref-type="bibr" rid="r29">29</xref>]. The probability of converting to PG was 10% at five years and 15% at 15 years.</p><p>PDS/PG is an autosomal dominant disorder and was mapped to the 7q35-q36 locus by linkage analysis [<xref ref-type="bibr" rid="r30">30</xref>], although the candidate gene is yet to be identified. While POAG shares several clinical features with PDS, there was no evidence of linkage to the POAG-associated 1q21-q31 locus in PDS, indicating that there would be other candidate loci that are yet uncharacterized [<xref ref-type="bibr" rid="r31">31</xref>,<xref ref-type="bibr" rid="r32">32</xref>].</p><p>XFS and PDS are two common disorders that can produce secondary glaucoma through trabecular blockage [<xref ref-type="bibr" rid="r22">22</xref>,<xref ref-type="bibr" rid="r33">33</xref>]. To further establish the specificity of this association, we studied the involvement of the three XFS- and XFG-associated <italic>LOXL1</italic> SNPs in a cohort of Caucasian PDS and PG patients from New York.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Clinical details of the subjects</title><p>The study protocol adhered to the tenets of the Declaration of Helsinki and was approved by the Institutional Review Boards of the New York Eye and Ear Infirmary (NYEE) and the L.V. Prasad Eye Institute. The cohort comprised 78 unrelated patients with PG (n=44) and PDS (n=34) seen at the NYEE between 1998 and 2003 along with 108 normal controls. The diagnoses of PDS/PG were independently confirmed by two surgeons based on the inclusion and exclusion criteria mentioned earlier [<xref ref-type="bibr" rid="r33">33</xref>]. The criteria for diagnosis of PDS required the presence of Krukenberg spindles, a deep anterior chamber, wide open angles on gonioscopy, and hyperpigmented trabecular meshwork. Transillumination defects were detected by infrared pupillography. A Zentmayer ring was considered to be confirmatory. A pigment reversal sign was only considered as a soft sign and not categorized as PDS. A diagnosis of PG required PDS plus typical glaucomatous optic disc and visual field damage.</p><p>Normal adult individuals without any signs or symptoms of glaucoma and other systemic diseases served as controls. Their visual acuity ranged from 20/20 to 20/40, and their IOP was less than 21&#x000a0;mmHg. The stereodisc exam did not reveal any changes in the optic disc suggestive of glaucoma. All the subjects underwent visual field testing with the Humphreys visual field analyzer (Carl Zeiss Meditec, Dublin, CA). This was essentially a diagnosis of exclusion: normal pattern of neuroretinal rim, absence of notching or thinning of the rim, and disc hemorrhage or nerve fiber layer defects. The cup/disc ratio related to the disc size, the asymmetry of cup to disc ratio less than or equal to 0.2:1 (corrected for size), and the absence of a beta zone peripapillary atrophy were &#x0201c;soft&#x0201d; signs. All the patients and controls were matched with respect to their ethnicity.</p></sec><sec><title>Molecular analysis</title><p>Peripheral blood samples (5&#x02013;10&#x000a0;ml) were collected from each subject by venipuncture with prior informed consent, and DNA was extracted by standard protocols [<xref ref-type="bibr" rid="r34">34</xref>]. The three SNPs in exon 1 (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1048661">rs1048661</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3825942">rs3825942</ext-link>) and intron 1 (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2165241">rs2165241</ext-link>) of <italic>LOXL1</italic> were amplified with pre-designed primers; the amplicons were purified and screened by re-sequencing using BigDye chemistry (version 3.1) on an ABI 3100 DNA Analyzer (Applied Biosystems, Foster City, CA) as described earlier [<xref ref-type="bibr" rid="r21">21</xref>]. The genotypes of a subset of patients and controls were further confirmed by restriction digestion of the amplicons at 37&#x000a0;&#x000b0;C overnight with appropriate restriction enzymes as detailed earlier [<xref ref-type="bibr" rid="r21">21</xref>]. The genotyping was repeated independently by investigators who were masked to the phenotypes. Representative chromatograms displaying all the genotype patterns for these three SNPs are provided in <xref ref-type="fig" rid="f1">Figure 1</xref> (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1048661">rs1048661</ext-link>), <xref ref-type="fig" rid="f2">Figure 2</xref> (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3825942">rs3825942</ext-link>), and <xref ref-type="fig" rid="f3">Figure 3</xref> (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2165241">rs2165241</ext-link>).</p><fig id="f1" fig-type="figure" position="float"><label>Figure 1</label><caption><p>Genotype pattern of the <italic>LOXL1</italic> SNP <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1048661">rs1048661</ext-link> (R141L). The representative electropherograms show the three genotype patterns for the <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1048661">rs1048661</ext-link> (G&#x0003e;T) SNP in <bold>A</bold> (TT; homozygous), <bold>B</bold> (GT; heterozygous), and <bold>C</bold> (GG; wild type). The arrow heads indicate the point of substitution. The normal sequence is provided in the upper panel above each electropherogram. <bold>D</bold> demonstrates the confirmation of these variants by PCR-based restriction digestion in a non-denaturing polyacrylamide gel. The PCR amplicon (464 bp) for <italic>LOXL1</italic> (obtained using the primer pairs 5&#x02032;-GCA GGT GTA CAG CTT GCT CA-3&#x02032; and 5&#x02032;-ACA CGA AAC CCT GGT CGT AG-3&#x02032;) after digestion with SmaI cleaved into fragments of 201 bp, 189 bp, and 74 bp in the wild type (lane 4). Presence of the variant abolished the site for this restriction enzyme, generating an intact fragment of 390 bp and 74 bp in the individual homozygous for this variant (lane 2). The individual with the heterozygous variant (lane 3) exhibits all the fragments (390 bp, 210 bp, 189 bp, and 74 bp). Lane 1 contains the 100 bp DNA ladder (Gene Ruler<sup>TM</sup>; MBI Fermentas, Vilnius, Lithuania).</p></caption><graphic xlink:href="mv-v14-1254-f1"/></fig><fig id="f2" fig-type="figure" position="float"><label>Figure 2</label><caption><p>Genotype pattern of the <italic>LOXL1</italic> SNP <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3825942">rs3825942</ext-link> (G153D). Representative electropherograms show the three genotype patterns for the <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3825942">rs3825942</ext-link> (G&#x0003e;A) SNP in <bold>A</bold> (GA; heterozygous), <bold>B</bold> (GG; wild type), and <bold>C</bold> (AA; homozygous). The arrow heads indicate the point of substitution. The normal sequence is provided in the upper panel above each electropherogram. <bold>D</bold> demonstrates the confirmation of these variants by PCR-based restriction digestion in a non-denaturing polyacrylamide gel. The PCR amplicon (464 bp) for <italic>LOXL1</italic> (obtained using the primer pairs 5&#x02032;-GCA GGT GTA CAG CTT GCT CA-3&#x02032; and 5&#x02032;-ACA CGA AAC CCT GGT CGT AG-3&#x02032;) after digestion with HinfI generated an intact fragment of 464 bp in the wild type (lane 3). Presence of the variation generated a restriction site for this enzyme and cleaved into fragments of 311 bp and 153 bp in the individual homozygous for this change (lane 4). The individual heterozygous for this change (lane 2) exhibited all three fragments (464 bp, 311 bp, and 153 bp). Lane 1 contains the 100 bp DNA ladder (Gene Ruler<sup>TM</sup>; MBI Fermentas, Vilnius, Lithuania).</p></caption><graphic xlink:href="mv-v14-1254-f2"/></fig><fig id="f3" fig-type="figure" position="float"><label>Figure 3</label><caption><p>Genotype pattern of the intronic <italic>LOXL1</italic> SNP <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2165241">rs2165241</ext-link>. Representative electropherograms show the three genotype patterns for the <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2165241">rs2165241</ext-link> (C&#x0003e;T) SNP in <bold>A</bold> (CC; wild type), <bold>B</bold> (TT; homozygous), and <bold>C</bold> (CT; heterozygous). The arrow heads indicate the point of substitution. The normal sequence is provided in the upper panel above each electropherogram. <bold>D</bold> demonstrates the confirmation of these variants by PCR-based restriction digestion in a non-denaturing polyacrylamide gel. The PCR amplicon (264 bp) for <italic>LOXL1</italic> (obtained using the primer pairs 5&#x02032;-TAG GGC CCC TTG GAG AAT AG-3&#x02032; and 5&#x02032;-GTC CCA TTC CCC TCT CAA TC-3&#x02032;) after digestion with SspI generated an intact fragment of 264 bp in the wild type (lane 1). Presence of the variation generated a restriction site for this enzyme and cleaved into fragments of 147 bp and 117 bp in the individual homozygous for this change (lane 2). The individual heterozygous for this change (lane 3) exhibited all three fragments (264 bp, 147 bp, and 117 bp). Lane 4 contains an undigested amplicon, and Lane 5 contains the 100 bp DNA ladder (Gene Ruler<sup>TM</sup>; MBI Fermentas, Vilnius, Lithuania).</p></caption><graphic xlink:href="mv-v14-1254-f3"/></fig></sec><sec><title>Statistical analysis</title><p>The maximum likelihood estimates of allele frequencies, Hardy&#x02013;Weinberg equilibrium, and haplotype frequencies were estimated from the genotype data at the three SNP loci using <ext-link ext-link-type="uri" xlink:href="http://www.broad.mit.edu/mpg/haploview">Haploview</ext-link> software that uses the expectation maximization (EM) algorithm [<xref ref-type="bibr" rid="r35">35</xref>]. Pairwise linkage disequilibrium (LD) between the individual SNPs was calculated using the LD-plot function of this software. &#x003c7;<sup>2</sup> analysis was done to assess the significance between the allele frequencies. The odds ratios were calculated to assess the risk of the individual alleles of all three SNPs.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Distribution of the <italic>LOXL1</italic> single nucleotide polymorphisms in pigment dispersion syndrome and pigmentary glaucoma</title><p>The study cohort conformed to the Hardy&#x02013;Weinberg equilibrium. The allele frequencies of the three SNPs and their corresponding allele counts are provided in <xref ref-type="table" rid="t1">Table 1</xref>. There was no significant difference in the frequencies of the XFS/XFG-associated alleles among the PG and PDS patients and controls. The allele frequencies were consistent even after categorizing the data set into PG and PDS phenotypes (<xref ref-type="table" rid="t1">Table 1</xref>). Similarly, there were no differences in the genotype frequencies of these alleles across these three <italic>LOXL1</italic> SNPs in PG and PDS cohorts (data not shown).</p><table-wrap id="t1" position="float"><label>Table 1</label><caption><title>Allele frequency distributions across PG/PDS cases and controls for the three <italic>LOXL1</italic> SNPs.</title></caption><table frame="hsides" rules="groups"><col width="90" span="1"/><col width="91" span="1"/><col width="88" span="1"/><col width="88" span="1"/><col width="84" span="1"/><tbody><tr><td rowspan="2" valign="top" align="center" scope="row" colspan="1"><bold>SNPs (Allele)</bold><hr/></td><td rowspan="2" valign="top" align="center" colspan="1"><bold>Phenotypes</bold><hr/></td><td colspan="2" valign="top" align="center" rowspan="1"><bold>Allele frequency (Counts)</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>p value</bold><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1"><bold>Cases</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Controls</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td rowspan="3" valign="top" align="center" scope="row" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1048661">rs1048661</ext-link>&#x02028; (G)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">PG+PDS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.674 (97/47)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.724 (152/58)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.309<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">PG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.679 (57/27)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.734 (152/58)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.439<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">PDS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.667 (40/20)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.724 (152/58)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.389<hr/></td></tr><tr><td rowspan="3" valign="top" align="center" scope="row" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3825942">rs3825942</ext-link>&#x02028; (G)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">PG+PDS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.852 (121/21)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.822 (176/38)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.461<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">PG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.866 (71/11)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.822 (176/38)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.368<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">PDS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.833 (50/10)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.822 (176/38)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.844<hr/></td></tr><tr><td rowspan="3" valign="top" align="center" scope="row" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2165241">rs2165241</ext-link>&#x02028; (T)</td><td valign="top" align="center" rowspan="1" colspan="1">PG+PDS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.514 (74/70)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.471 (99/111)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.432<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">PG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.524 (44/40)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.471 (99/111)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.417<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">PDS</td><td valign="top" align="center" rowspan="1" colspan="1">0.500 (30/30)</td><td valign="top" align="center" rowspan="1" colspan="1">0.471 (99/111)</td><td valign="top" align="center" rowspan="1" colspan="1">0.91</td></tr></tbody></table></table-wrap></sec><sec><title>Haplotype analysis of the <italic>LOXL1</italic> single nucleotide polymorphisms</title><p>Haplotypes were generated with the three <italic>LOXL1</italic> intragenic SNPs among PG/PDS cases and controls. There was a strong pairwise linkage disequilibrium (LD) between the <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1048661">rs1048661</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3825942">rs3825942</ext-link> (D&#x02019;=0.89, 95%CI, 0.57&#x02013;0.97) SNPs and between the <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3825942">rs3825942</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2165241">rs2165241</ext-link> (D&#x02019;=1.00, 95%CI, 0.81&#x02013;1.00) SNPs, similar to earlier studies [<xref ref-type="bibr" rid="r11">11</xref>-<xref ref-type="bibr" rid="r15">15</xref>,<xref ref-type="bibr" rid="r17">17</xref>-<xref ref-type="bibr" rid="r20">20</xref>].</p><p>Four different haplotypes could be generated (with frequency greater than 5%) with these three SNPs in PG/PDS patients and controls. There were no significant differences in the haplotype frequencies between the cases and controls. These results were consistent even after reanalysis of the haplotype data with respect to PG and PDS phenotypes and controls (<xref ref-type="table" rid="t2">Table 2</xref>).</p><table-wrap id="t2" position="float"><label>Table 2</label><caption><title>Estimated <italic>LOXL1</italic> haplotype frequencies of PG/PDS patients and controls.</title></caption><table frame="hsides" rules="groups"><col width="90" span="1"/><col width="91" span="1"/><col width="86" span="1"/><col width="90" span="1"/><col width="83" span="1"/><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Haplotypes</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Phenotypes</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>%Cases</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>%Controls</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>p value</bold><hr/></td></tr><tr><td rowspan="3" valign="top" align="left" scope="row" colspan="1">G-G-T<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">PG+PDS<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">46.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">45.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.881<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">PG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">48<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">45.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.729<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">PDS<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">44.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">45.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.883<hr/></td></tr><tr><td rowspan="3" valign="top" align="left" scope="row" colspan="1">T-G-C<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">PG+PDS<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">27.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">24.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.511<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">PG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">27.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">24.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.683<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">PDS<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">29.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">24.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.495<hr/></td></tr><tr><td rowspan="3" valign="top" align="left" scope="row" colspan="1">G-A-C<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">PG+PDS<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">13.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">16.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.451<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">PG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">12.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">16.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.364<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">PDS<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">15.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">16.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.831<hr/></td></tr><tr><td rowspan="3" valign="top" align="left" scope="row" colspan="1">G-G-C</td><td valign="top" align="left" rowspan="1" colspan="1">PG+PDS<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">10<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.464<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">PG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">10<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.483<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">PDS</td><td valign="top" align="left" rowspan="1" colspan="1">8.1</td><td valign="top" align="left" rowspan="1" colspan="1">9.9</td><td valign="top" align="left" rowspan="1" colspan="1">0.662</td></tr></tbody></table></table-wrap></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>XFS is the most common identifiable cause of open-angle glaucoma worldwide. It is also associated with extra-ocular abnormalities [<xref ref-type="bibr" rid="r36">36</xref>,<xref ref-type="bibr" rid="r37">37</xref>]. Recently, intragenic SNPs in <italic>LOXL1</italic> were implicated in XFS and XFG in an Icelandic and Swedish population [<xref ref-type="bibr" rid="r9">9</xref>]. Several studies conducted on XFS and XFG worldwide were able to independently replicate these findings in geographically and ethnically diverse cohorts [<xref ref-type="bibr" rid="r10">10</xref>-<xref ref-type="bibr" rid="r19">19</xref>]. Since <italic>LOXL1</italic> SNPs were implicated in a secondary glaucoma, we analyzed these variations in PDS/PG to establish the uniqueness of this association. To the best of our knowledge, this is the first report to screen for these SNPs in PG/PDS.</p><p>The data from the present study show that the three XFS/XFG-associated SNPs were not involved with PG or PDS. The significant associations of the <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1048661">rs1048661</ext-link> (G allele) and the <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3825942">rs3825942</ext-link> (G allele) SNPs have been consistent to XFS and XFG across multiple populations worldwide except in Japanese (<xref ref-type="table" rid="t3">Table 3</xref>). On the contrary, the &#x0201c;T&#x0201d; allele (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1048661">rs1048661</ext-link>) has exhibited strong association with the Japanese XFS/XFG patients [<xref ref-type="bibr" rid="r16">16</xref>,<xref ref-type="bibr" rid="r19">19</xref>]. So far, these SNPs have not been involved with primary glaucomas [<xref ref-type="bibr" rid="r9">9</xref>,<xref ref-type="bibr" rid="r12">12</xref>,<xref ref-type="bibr" rid="r20">20</xref>,<xref ref-type="bibr" rid="r21">21</xref>]. However, the allele frequencies of the <italic>LOXL1</italic> SNPs in PG/PDS patients were similar to that observed in primary glaucomas (<xref ref-type="table" rid="t3">Table 3</xref>).</p><table-wrap id="t3" position="float"><label>Table 3</label><caption><title>Worldwide distribution of allele frequencies and their odds ratios for the three <italic>LOXL1</italic> SNPs across all glaucoma phenotypes including the present cohort.</title></caption><table frame="hsides" rules="groups"><col width="68" span="1"/><col width="72" span="1"/><col width="67" span="1"/><col width="40" span="1"/><col width="72" span="1"/><col width="63" span="1"/><col width="46" span="1"/><col width="90" span="1"/><col width="67" span="1"/><col width="46" span="1"/><col width="76" span="1"/><col width="57" span="1"/><col width="63" span="1"/><tbody><tr><td rowspan="2" valign="top" align="left" scope="row" colspan="1"><bold>Type of glaucoma</bold><hr/></td><td rowspan="2" valign="top" align="left" colspan="1"><bold>Phenotypes</bold><hr/></td><td rowspan="2" valign="top" align="left" colspan="1"><bold>Population [n cases]</bold><hr/></td><td colspan="3" valign="top" align="center" rowspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1048661">rs1048661</ext-link>&#x02028; <bold>(G)</bold><hr/></td><td colspan="3" valign="top" align="center" rowspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3825942">rs3825942</ext-link>&#x02028; <bold>(G)</bold><hr/></td><td colspan="3" valign="top" align="center" rowspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2165241">rs2165241</ext-link>&#x02028; <bold>(T)</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Reference</bold><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1"><bold>Freq</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>OR</bold>&#x02028;<bold>(95% CI)</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>p value</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Freq</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>OR</bold>&#x02028;<bold>(95%CI)</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>p value</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Freq</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>OR (95%CI)</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>p value</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td rowspan="8" valign="top" align="left" scope="row" colspan="1">Primary<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">POAG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Iceland [n=90]<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.711<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.32&#x02028;(0.96&#x02013;1.82)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.085<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.872<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.25&#x02028;(0.81&#x02013;1.91)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.32<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.55<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.36&#x02028;(1.01&#x02013;1.83)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.04<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r9">9</xref>]<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">POAG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Sweden [n=200]<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.638<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.82&#x02028;(0.61&#x02013;1.10)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.19<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.863<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.87&#x02028;(0.57&#x02013;1.31)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.49<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.488<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.83&#x02028;(0.63&#x02013;1.09)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.18<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r9">9</xref>]<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">POAG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">India [n=112]<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.616<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.70&#x02028;(0.40&#x02013;1.24)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.112<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.83<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.53&#x02028;(0.78&#x02013;2.98)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.105<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.321<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.95&#x02028;(0.54&#x02013;1.67)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.426<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r20">20</xref>]<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">PACG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">India [n=96]<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.667<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.88&#x02028;(0.49&#x02013;1.59)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.332<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.755<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.94&#x02028;(0.49&#x02013;1.79)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.456<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.296<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.82&#x02028;(0.45&#x02013;1.50)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.262<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r20">20</xref>]<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">POAG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">USA [n=331]<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.724<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.02&#x02028;(0.70&#x02013;1.51)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.92<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.771<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.86&#x02028;(0.57&#x02013;1.30)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.54<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.412<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.83&#x02028;(0.59&#x02013;1.18)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.33<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r12">12</xref>]<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">POAG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Caucasians [n=279]<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.829<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.583<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.424<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.056<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r21">21</xref>]<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">POAG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">African-Americans [n=193]<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.617<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.591<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.237<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.408<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r21">21</xref>]<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">POAG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Africans [n=170]<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.622<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.217<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.226<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.472<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r21">21</xref>]<hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td rowspan="14" valign="top" align="left" scope="row" colspan="1">Secondary</td><td valign="top" align="left" rowspan="1" colspan="1">XFS<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Iceland [n=55]<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.789<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2.02&#x02028;(1.32&#x02013;3.09)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.3x10<sup>&#x02212;3</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.982<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">10.1&#x02028;(4.02&#x02013;25.36)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">8.5x10<sup>&#x02212;7</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.74<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3.18&#x02028;(2.12&#x02013;4.76)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.9x10<sup>&#x02212;8</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r9">9</xref>]<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">XFG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Iceland [n=75]<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.827<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2.56&#x02028;(1.74&#x02013;3.77)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.8x10<sup>&#x02212;6</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.987<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">13.2&#x02028;(5.59&#x02013;31.29)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4.1x10<sup>&#x02212;9</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.753<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3.40&#x02028;(2.41&#x02013;4.81)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4.3x10<sup>&#x02212;12</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r9">9</xref>]<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">XFG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Sweden [n=199]<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.834<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2.39&#x02028;(1.72&#x02013;3.34)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2.7x10<sup>&#x02212;7</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.995<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">27.3&#x02028;(11.4&#x02013;65.07)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">9.1x10<sup>&#x02212;14</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.813<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3.78&#x02028;(2.77&#x02013;5.14)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3.1x10<sup>&#x02212;17</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r9">9</xref>]<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">XFS<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">USA [n=72]<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.819<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3.03&#x02028;(1.77&#x02013;5.17)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.00003<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.986<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">9.68&#x02028;(2.20&#x02013;42.53)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.0003<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r10">10</xref>]<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">XFG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">USA [n=50]<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.787<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.86&#x02028;(1.10&#x02013;3.15)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.0222<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.939<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3.05&#x02028;(1.20&#x02013;7.76)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.0194<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.667<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2.30&#x02028;(1.40&#x02013;3.76)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.001<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r11">11</xref>]<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">XFS/XFG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">USA [n=206]<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.829<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.90&#x02028;(1.23&#x02013;2.93)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.005<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.988<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">20.9&#x02028;(8.06&#x02013;54.39)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.6x10<sup>&#x02212;15</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.76<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3.77&#x02028;(2.56&#x02013;5.55)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.2x10<sup>&#x02212;11</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r12">12</xref>]<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">XFS/XFG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">American and European [n=287]<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.843<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2.26&#x02028;(1.71&#x02013;2.99)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">7.74x10<sup>&#x02212;9</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.959<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5.97&#x02028;(3.77&#x02013;9.44)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3.1x10<sup>&#x02212;17</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.734<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2.24&#x02028;(1.76&#x02013;2.86)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4.8x10<sup>&#x02212;24</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r13">13</xref>]<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">XFS/XFG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Germany and Italy [n=726]<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.82<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2.43&#x02028;(2.00&#x02013;2.97)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2.9x10<sup>&#x02212;19</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.965<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4.87&#x02028;(3.46&#x02013;6.85)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">8.2x10<sup>&#x02212;23</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.765<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3.42&#x02028;(2.85&#x02013;4.11)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.9x10<sup>&#x02212;40</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r14">14</xref>]<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">XFG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Europe [n=167]<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.841<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2.69&#x02028;(1.59&#x02013;4.54)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">9.91x10<sup>&#x02212;19</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.994<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">37.29&#x02028;(6.35&#x02013;218.02)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5.76x10<sup>&#x02212;15</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r18">18</xref>]<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">XFS/XFG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">India [n=50]<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.72<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.49&#x02028;(0.89&#x02013;2.51)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.156<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.92<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4.17&#x02028;(1.89&#x02013;9.18)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.0001<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r15">15</xref>]<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">XFS/XFG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Japan [n=59]<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.008<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r16">16</xref>]<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">XFS/XFG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Japan [n=209]<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.053<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.986<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">10.87&#x02028;(4.59&#x02013;27.25)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.30x10<sup>&#x02212;11</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.017<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r19">19</xref>]<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">XFS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Australia [n=86]<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.78<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.86&#x02028;(1.27&#x02013;2.76)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">8.5x10<sup>&#x02212;4</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.95<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3.81&#x02028;(1.88&#x02013;9.02)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">7.8x10<sup>&#x02212;5</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r17">17</xref>]<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">PG/PDS</td><td valign="top" align="left" rowspan="1" colspan="1">USA [n=78]</td><td valign="top" align="left" rowspan="1" colspan="1">0.674</td><td valign="top" align="center" rowspan="1" colspan="1">0.79&#x02028;(0.49&#x02013;1.25)</td><td valign="top" align="center" rowspan="1" colspan="1">0.309</td><td valign="top" align="center" rowspan="1" colspan="1">0.852</td><td valign="top" align="center" rowspan="1" colspan="1">1.24&#x02028;(0.69&#x02013;2.22)</td><td valign="top" align="center" rowspan="1" colspan="1">0.461</td><td valign="top" align="center" rowspan="1" colspan="1">0.514</td><td valign="top" align="center" rowspan="1" colspan="1">1.18&#x02028;(0.77&#x02013;1.81)</td><td valign="top" align="center" rowspan="1" colspan="1">0.432</td><td valign="top" align="center" rowspan="1" colspan="1">Present study</td></tr></tbody></table></table-wrap><p>There was no significant association with the <italic>LOXL1</italic> haplotypes either with PG or PDS (<xref ref-type="table" rid="t2">Table 2</xref>). Since most studies had demonstrated a significant risk with haplotypes generated with the <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1048661">rs1048661</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3825942">rs3825942</ext-link> SNPs [<xref ref-type="bibr" rid="r9">9</xref>-<xref ref-type="bibr" rid="r15">15</xref>,<xref ref-type="bibr" rid="r17">17</xref>-<xref ref-type="bibr" rid="r19">19</xref>], a similar exercise was conducted to draw a comparison of the haplotype structure in the present cohort with other studies. The frequency of the risk haplotype with these two SNPs (G-G) was observed in lower frequency among the PG/PDS patients compared to other studies; this risk haplotype was also present in ~55% of the control subjects (<xref ref-type="table" rid="t4">Table 4</xref>). Unlike previous studies on XFS and XFG, there was no risk associated with the G-G (OR=1.08, 95%CI, 0.59&#x02013;1.97) and T-G (OR=1.35, 95%CI, 0.70&#x02013;2.60) haplotypes in PG/PDS (<xref ref-type="table" rid="t4">Table 4</xref>).</p><table-wrap id="t4" position="float"><label>Table 4</label><caption><title>The estimated haplotype frequencies and their odds ratios based on two SNPs (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1048661">rs1048661</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3825942">rs3825942</ext-link>) across different secondary glaucoma phenotypes in the present cohort and other populations.</title></caption><table frame="hsides" rules="groups"><col width="74" span="1"/><col width="60" span="1"/><col width="41" span="1"/><col width="63" span="1"/><col width="81" span="1"/><col width="63" span="1"/><col width="52" span="1"/><col width="67" span="1"/><col width="77" span="1"/><col width="60" span="1"/><col width="64" span="1"/><tbody><tr><td rowspan="2" valign="top" align="left" scope="row" colspan="1"><bold>Populations, [n (cases, controls)]</bold><hr/></td><td rowspan="2" valign="top" align="left" colspan="1"><bold>Pheno-types</bold><hr/></td><td colspan="4" valign="top" align="center" rowspan="1"><bold>G-G haplotype</bold><hr/></td><td colspan="4" valign="top" align="center" rowspan="1"><bold>T-G haplotype</bold><hr/></td><td rowspan="2" valign="top" align="center" colspan="1"><bold>Reference</bold><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1"><bold>% Cases</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>% Controls</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>OR (95%CI)*</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>p value</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>%Cases</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>%Controls</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>OR (95%CI)*</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>p value</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Sweden [399,198]<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">XFG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">83.3<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">56.1<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">35.72#<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2.2x10<sup>&#x02212;16</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">16.2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">31.8<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">12.36#<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.6x10<sup>&#x02212;6</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r9">9</xref>]<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Iceland [195,14474]<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">XFG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">81.4<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">49.8<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">18.94#<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3.3x10<sup>&#x02212;12</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">17.3<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">34.9<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5.74#<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.0027<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r9">9</xref>]<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">USA [72,75]<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">XFS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">80.6<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">48<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">14.50&#x02028;(3.27&#x02013;64.35)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2.7x10<sup>&#x02212;5</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">18.1<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">40<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3.90&#x02028;(0.84&#x02013;18.04)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.12<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r10">10</xref>]<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">American and European [566,658]<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">XFS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">80.2<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">50.3<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4.00&#x02028;(3.10&#x02013;5.18)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.5x10<sup>&#x02212;7</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">15.7<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">29.6<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.44&#x02028;(0.33&#x02013;0.59)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">9.0x10<sup>&#x02212;9</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r13">13</xref>]<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Germany and Italy [726,418]<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">XFS/XFG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">78.6<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">50.7<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3.58&#x02028;(2.98&#x02013;4.32)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5.2x10<sup>&#x02212;43</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">17.9<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">34.6<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r14">14</xref>]<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Europe [167,170]<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">XFG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">83.5<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">48.8<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">52.1&#x02028;(13.85&#x02013;195.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">15.9<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">32.9<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">14.67&#x02028;(3.81&#x02013;56.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r18">18</xref>]<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">India [52,97]<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">XFS/XFG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">64<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">37<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5.74&#x02028;(2.53&#x02013;12.98)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">9.9x10<sup>&#x02212;6</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">27<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">36<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2.55&#x02028;(1.07&#x02013;6.05)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.129<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r15">15</xref>]<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Australia [86,2422]<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">XFS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">74<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">51<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2.71&#x02028;(1.91&#x02013;3.92)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3.8x10<sup>&#x02212;9</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">22<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">34<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.54&#x02028;(0.36&#x02013;0.78)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">7.8x10<sup>&#x02212;4</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"> [<xref ref-type="bibr" rid="r17">17</xref>]<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">USA [78, 108]</td><td valign="top" align="left" rowspan="1" colspan="1">PG/PDS</td><td valign="top" align="center" rowspan="1" colspan="1">52.9</td><td valign="top" align="center" rowspan="1" colspan="1">55.3</td><td valign="top" align="center" rowspan="1" colspan="1">1.08&#x02028;(0.59&#x02013;1.97)</td><td valign="top" align="center" rowspan="1" colspan="1">0.643</td><td valign="top" align="center" rowspan="1" colspan="1">32.3</td><td valign="top" align="center" rowspan="1" colspan="1">26.9</td><td valign="top" align="center" rowspan="1" colspan="1">1.35&#x02028;(0.70&#x02013;2.60)</td><td valign="top" align="center" rowspan="1" colspan="1">0.266</td><td valign="top" align="center" rowspan="1" colspan="1">Present study</td></tr></tbody></table><table-wrap-foot><p>The asterisk indicates that the odds ratios were calculated with respect to the G-A haplotype. The sharp (hash mark) indicated that the 95%CI were not available in the reported studies.</p></table-wrap-foot></table-wrap><p>While PG/PDS occurs relatively early in life, XFS/XFG occurs at a later stage. It has been suggested that certain PDS patients who do not achieve IOP control could later progress to develop XFS/XFG [<xref ref-type="bibr" rid="r38">38</xref>]. Based on this, the concept of an &#x0201c;overlap&#x0201d; syndrome has been suggested whereby the sequential appearance of two or more risk factors lead to glaucomatous damage [<xref ref-type="bibr" rid="r33">33</xref>].</p><p>In summary, we aimed to determine if the <italic>LOXL1</italic> SNPs associated with XFS/XFG were involved in another secondary glaucoma. The high population attributable risks for the high-risk haplotype among the diverse XFS/XFG patients strongly suggest that these variants are exclusive to XFS and XFG [<xref ref-type="bibr" rid="r9">9</xref>,<xref ref-type="bibr" rid="r13">13</xref>]. The non-association of the <italic>LOXL1</italic> SNPs in our PG/PDS cohort further supports the fact that these are XFS-specific and may not be involved with other secondary glaucomas. Although PG/PDS share certain discrete clinical features with XFS, their underlying molecular mechanisms remain to be elucidated.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank all the patients and the normal volunteers for their participation in this study. The authors would like to take this opportunity to thank Dr. Mansoor Sarfarazi (University of Connecticut Health Center, Farmington, CT) for providing the <italic>LOXL1</italic> genotype data for 50 control samples. The study was supported by grants from the Department of Biotechnology (BT/01/COE/06/02/10), Government of India to S.C., and the Daniel Hebert Glaucoma Research Fund of the New York Eye and Ear Infirmary to R.R.</p></ack><ref-list><title>References</title><ref id="r1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Libby</surname><given-names>RT</given-names></name><name><surname>Gould</surname><given-names>DB</given-names></name><name><surname>Anderson</surname><given-names>MG</given-names></name><name><surname>John</surname><given-names>SW</given-names></name></person-group><article-title>Complex genetics of glaucoma susceptibility.</article-title><source>Annu Rev Genomics Hum Genet</source><year>2005</year><volume>6</volume><fpage>15</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">16124852</pub-id></citation></ref><ref id="r2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>BE</given-names></name><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Sponsel</surname><given-names>WE</given-names></name><name><surname>Franke</surname><given-names>T</given-names></name><name><surname>Camtor</surname><given-names>LB</given-names></name><name><surname>Martone</surname><given-names>J</given-names></name><name><surname>Menage</surname><given-names>MJ</given-names></name></person-group><article-title>Prevalence of glaucoma. The Beaver Dam Eye Study.</article-title><source>Ophthalmology</source><year>1992</year><volume>99</volume><fpage>1499</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">1454314</pub-id></citation></ref><ref id="r3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Quigley</surname><given-names>HA</given-names></name><name><surname>Broman</surname><given-names>AT</given-names></name></person-group><article-title>The number of people with glaucoma worldwide in 2010 and 2020.</article-title><source>Br J Ophthalmol</source><year>2006</year><volume>90</volume><fpage>262</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16488940</pub-id></citation></ref><ref id="r4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ritch</surname><given-names>R</given-names></name></person-group><article-title>Exfoliation syndrome: The most common identifiable cause of open-angle glaucoma.</article-title><source>J Glaucoma</source><year>1994</year><volume>3</volume><fpage>176</fpage><lpage>8</lpage></citation></ref><ref id="r5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Linn&#x000e9;r</surname><given-names>E</given-names></name><name><surname>Popovic</surname><given-names>V</given-names></name><name><surname>Gottfries</surname><given-names>CG</given-names></name><name><surname>Jonsson</surname><given-names>M</given-names></name><name><surname>Sjogren</surname><given-names>M</given-names></name><name><surname>Wallin</surname><given-names>A</given-names></name></person-group><article-title>The exfoliation syndrome in cognitive impairment of cerebrovascular or Alzheimer&#x02019;s type.</article-title><source>Acta Ophthalmol Scand</source><year>2001</year><volume>79</volume><fpage>283</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">11401639</pub-id></citation></ref><ref id="r6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aydogan Ozkan</surname><given-names>B</given-names></name><name><surname>Yuksel</surname><given-names>N</given-names></name><name><surname>Keskin</surname><given-names>G</given-names></name><name><surname>Altintas</surname><given-names>O</given-names></name><name><surname>Karabas</surname><given-names>VL</given-names></name><name><surname>Caglar</surname><given-names>Y</given-names></name><name><surname>Almac</surname><given-names>A</given-names></name></person-group><article-title>Homocysteine levels in plasma and sensorineural hearing loss in patients with pseudoexfoliation syndrome.</article-title><source>Eur J Ophthalmol</source><year>2006</year><volume>16</volume><fpage>542</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16952092</pub-id></citation></ref><ref id="r7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Irkec</surname><given-names>M</given-names></name></person-group><article-title>Exfoliation and carotid stiffness.</article-title><source>Br J Ophthalmol</source><year>2006</year><volume>90</volume><fpage>529</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">16556616</pub-id></citation></ref><ref id="r8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yazdani</surname><given-names>S</given-names></name><name><surname>Tousi</surname><given-names>A</given-names></name><name><surname>Pakravan</surname><given-names>M</given-names></name><name><surname>Faghihi</surname><given-names>A</given-names></name></person-group><article-title>Sensorineural hearing loss in pseudoexfoliation syndrome.</article-title><source>Ophthalmology</source><year>2008</year><volume>115</volume><fpage>425</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18187196</pub-id></citation></ref><ref id="r9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thorleifsson</surname><given-names>G</given-names></name><name><surname>Magnusson</surname><given-names>KP</given-names></name><name><surname>Sulem</surname><given-names>P</given-names></name><name><surname>Walters</surname><given-names>GB</given-names></name><name><surname>Gudbjartsson</surname><given-names>DF</given-names></name><name><surname>Stefansson</surname><given-names>H</given-names></name><name><surname>Jonsson</surname><given-names>T</given-names></name><name><surname>Jonasdottir</surname><given-names>A</given-names></name><name><surname>Jonasdottir</surname><given-names>A</given-names></name><name><surname>Stefansdottir</surname><given-names>G</given-names></name><name><surname>Masson</surname><given-names>G</given-names></name><name><surname>Hardarson</surname><given-names>GA</given-names></name><name><surname>Petursson</surname><given-names>H</given-names></name><name><surname>Arnarsson</surname><given-names>A</given-names></name><name><surname>Motallebipour</surname><given-names>M</given-names></name><name><surname>Wallerman</surname><given-names>O</given-names></name><name><surname>Wadelius</surname><given-names>C</given-names></name><name><surname>Gulcher</surname><given-names>JR</given-names></name><name><surname>Thorsteinsdottir</surname><given-names>U</given-names></name><name><surname>Kong</surname><given-names>A</given-names></name><name><surname>Jonasson</surname><given-names>F</given-names></name><name><surname>Stefansson</surname><given-names>K</given-names></name></person-group><article-title>Common sequence variants in the <italic>LOXL1</italic> gene confer susceptibility to exfoliation glaucoma.</article-title><source>Science</source><year>2007</year><volume>317</volume><fpage>1397</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">17690259</pub-id></citation></ref><ref id="r10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fingert</surname><given-names>JH</given-names></name><name><surname>Alward</surname><given-names>WLM</given-names></name><name><surname>Kwon</surname><given-names>YH</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Streb</surname><given-names>LM</given-names></name><name><surname>Sheffield</surname><given-names>VC</given-names></name><name><surname>Stoe</surname><given-names>EM</given-names></name></person-group><article-title><italic>LOXL1</italic> mutations are associated with exfoliation syndrome in patients from Midwestern United States.</article-title><source>Am J Ophthalmol</source><year>2007</year><volume>144</volume><fpage>974</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">18036875</pub-id></citation></ref><ref id="r11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Challa</surname><given-names>P</given-names></name><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Qin</surname><given-names>X</given-names></name><name><surname>Vann</surname><given-names>RR</given-names></name><name><surname>Gonzalez</surname><given-names>P</given-names></name><name><surname>Allingham</surname><given-names>RR</given-names></name><name><surname>Hauser</surname><given-names>MA</given-names></name></person-group><article-title>Analysis of <italic>LOXL1</italic> polymorphisms in a United States population with pseudoexfoliation glaucoma.</article-title><source>Mol Vis</source><year>2008</year><volume>14</volume><fpage>146</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18334928</pub-id></citation></ref><ref id="r12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>BJ</given-names></name><name><surname>Pasquale</surname><given-names>L</given-names></name><name><surname>Grosskreutz</surname><given-names>CL</given-names></name><name><surname>Rhee</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>DeAngelis</surname><given-names>MM</given-names></name><name><surname>Kim</surname><given-names>I</given-names></name><name><surname>del Bono</surname><given-names>E</given-names></name><name><surname>Miller</surname><given-names>JW</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Wiggs</surname><given-names>JL</given-names></name></person-group><article-title>DNA sequence variants in the <italic>LOXL1</italic> gene are associated with pseudoexfoliation glaucoma in a U.S. clinic-based population with broad ethnic diversity.</article-title><source>BMC Med Genet</source><year>2008</year><volume>9</volume><fpage>5</fpage><pub-id pub-id-type="pmid">18254956</pub-id></citation></ref><ref id="r13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aragon-Martin</surname><given-names>JA</given-names></name><name><surname>Ritch</surname><given-names>R</given-names></name><name><surname>Liebmann</surname><given-names>J</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>C</given-names></name><name><surname>Blaaow</surname><given-names>K</given-names></name><name><surname>Mercieca</surname><given-names>F</given-names></name><name><surname>Spiteri</surname><given-names>A</given-names></name><name><surname>Cobb</surname><given-names>CJ</given-names></name><name><surname>Damji</surname><given-names>KF</given-names></name><name><surname>Tarkkanen</surname><given-names>A</given-names></name><name><surname>Rezaie</surname><given-names>T</given-names></name><name><surname>Child</surname><given-names>AC</given-names></name><name><surname>Sarfarazi</surname><given-names>M</given-names></name></person-group><article-title>Evaluation of <italic>LOXL1</italic> gene polymorphisms in exfoliation syndrome and exfoliation glaucoma.</article-title><source>Mol Vis</source><year>2008</year><volume>14</volume><fpage>533</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">18385788</pub-id></citation></ref><ref id="r14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pasutto</surname><given-names>F</given-names></name><name><surname>Krumbiegel</surname><given-names>M</given-names></name><name><surname>Mardin</surname><given-names>CY</given-names></name><name><surname>Paoli</surname><given-names>D</given-names></name><name><surname>Lammer</surname><given-names>R</given-names></name><name><surname>Weber</surname><given-names>BHF</given-names></name><name><surname>Kruse</surname><given-names>FE</given-names></name><name><surname>Schlotzer-Schrehardt</surname><given-names>U</given-names></name><name><surname>Reis</surname><given-names>A</given-names></name></person-group><article-title>Association of <italic>LOXL1</italic> common sequence variations in German and Italian patients with pseudoexfoliation syndrome and pseudoexfoliation glaucoma.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2008</year><volume>49</volume><fpage>1459</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">18385063</pub-id></citation></ref><ref id="r15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramprasad</surname><given-names>VL</given-names></name><name><surname>George</surname><given-names>R</given-names></name><name><surname>Soumittra</surname><given-names>N</given-names></name><name><surname>Sharmila</surname><given-names>F</given-names></name><name><surname>Vijaya</surname><given-names>L</given-names></name><name><surname>Kumaramanickavel</surname><given-names>G</given-names></name></person-group><article-title>Association of non-synonymous single nucleotide polymorphisms in the <italic>LOXL1</italic> gene with pseudoexfoliation syndrome in India.</article-title><source>Mol Vis</source><year>2008</year><volume>14</volume><fpage>318</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">18334947</pub-id></citation></ref><ref id="r16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>H</given-names></name><name><surname>Gotoh</surname><given-names>N</given-names></name><name><surname>Ueda</surname><given-names>Y</given-names></name><name><surname>Nakanishi</surname><given-names>H</given-names></name><name><surname>Yoshimura</surname><given-names>N</given-names></name></person-group><article-title>Lysyl Oxidase-like 1 polymorphisms and exfoliation syndrome in the Japanese population.</article-title><source>Am J Ophthalmol</source><year>2008</year><volume>145</volume><fpage>582</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">18201684</pub-id></citation></ref><ref id="r17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hewitt</surname><given-names>AW</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Burdon</surname><given-names>KP</given-names></name><name><surname>Wang</surname><given-names>JJ</given-names></name><name><surname>Baird</surname><given-names>PN</given-names></name><name><surname>Dimasi</surname><given-names>DP</given-names></name><name><surname>Mackey</surname><given-names>DA</given-names></name><name><surname>Mitchell</surname><given-names>P</given-names></name><name><surname>Craig</surname><given-names>JE</given-names></name></person-group><article-title>Ancestral <italic>LOXL1</italic> variants are associated with pseudoexfoliation in Caucasian Australians but with markedly lower penetrance than in Nordic people.</article-title><source>Hum Mol Genet</source><year>2007</year><volume>17</volume><fpage>710</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">18037624</pub-id></citation></ref><ref id="r18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mossbock</surname><given-names>G</given-names></name><name><surname>Renner</surname><given-names>W</given-names></name><name><surname>Faschinger</surname><given-names>C</given-names></name><name><surname>Schmut</surname><given-names>O</given-names></name><name><surname>Wedrich</surname><given-names>A</given-names></name><name><surname>Weger</surname><given-names>M</given-names></name></person-group><article-title>Lysyl oxidase-like protein 1 (LOXL1) gene polymorphisms and exfoliation glaucoma in a Central European population.</article-title><source>Mol Vis</source><year>2008</year><volume>14</volume><fpage>857</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">18483563</pub-id></citation></ref><ref id="r19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ozaki</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>KY</given-names></name><name><surname>Vithana</surname><given-names>EN</given-names></name><name><surname>Yong</surname><given-names>VH</given-names></name><name><surname>Thalamuthu</surname><given-names>A</given-names></name><name><surname>Mizoguchi</surname><given-names>T</given-names></name><name><surname>Venkatraman</surname><given-names>A</given-names></name><name><surname>Aung</surname><given-names>T</given-names></name></person-group><article-title>Association of LOXL1 gene polymorphisms with pseudoexfoliation in the Japanese.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2008</year>[Epub ahead of print]<pub-id pub-id-type="pmid">18450598</pub-id></citation></ref><ref id="r20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chakrabarti</surname><given-names>S</given-names></name><name><surname>Rao</surname><given-names>KN</given-names></name><name><surname>Kaur</surname><given-names>I</given-names></name><name><surname>Parikh</surname><given-names>RS</given-names></name><name><surname>Mandal</surname><given-names>AK</given-names></name><name><surname>Chandrasekhar</surname><given-names>G</given-names></name><name><surname>Thomas</surname><given-names>R</given-names></name></person-group><article-title>The LOXL1 gene variations are not associated with primary open-angle and primary angle-closure glaucomas.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2008</year><volume>49</volume><fpage>2343</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">18223248</pub-id></citation></ref><ref id="r21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Qin</surname><given-names>X</given-names></name><name><surname>Gibson</surname><given-names>JR</given-names></name><name><surname>Hutchins</surname><given-names>K</given-names></name><name><surname>Santiago-Turla</surname><given-names>C</given-names></name><name><surname>Wiggs</surname><given-names>JL</given-names></name><name><surname>Budenz</surname><given-names>DL</given-names></name><name><surname>Akafo</surname><given-names>S</given-names></name><name><surname>Challa</surname><given-names>P</given-names></name><name><surname>Herndon</surname><given-names>LW</given-names></name><name><surname>Hauser</surname><given-names>MA</given-names></name><name><surname>Allingham</surname><given-names>RR</given-names></name></person-group><article-title>Lack of association between LOXL1 variants and primary open-angle glaucoma in three different populations.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2008</year><pub-id pub-id-type="pmid">18421074</pub-id></citation></ref><ref id="r22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>DG</given-names></name></person-group><article-title>Pigmentary dispersion and glaucoma: a new theory.</article-title><source>Arch Ophthalmol</source><year>1979</year><volume>97</volume><fpage>1667</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">475638</pub-id></citation></ref><ref id="r23"><label>23</label><citation citation-type="book">Ritch R. Pigment dispersion syndrome. In: Grehn F, Stamper R, editors. Glaucoma&#x02013;update 2003. Berlin: Springer-Verlag; 2004. p. 177&#x02013;92.</citation></ref><ref id="r24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liebmann</surname><given-names>JM</given-names></name><name><surname>Tello</surname><given-names>C</given-names></name><name><surname>Chew</surname><given-names>SJ</given-names></name><name><surname>Cohen</surname><given-names>H</given-names></name><name><surname>Ritch</surname><given-names>R</given-names></name></person-group><article-title>Prevention of blinking alters iris configuration in pigment dispersion syndrome and in normal eyes.</article-title><source>Ophthalmology</source><year>1995</year><volume>102</volume><fpage>446</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">7891984</pub-id></citation></ref><ref id="r25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Migliazzo</surname><given-names>CV</given-names></name><name><surname>Shaffer</surname><given-names>RN</given-names></name><name><surname>Nykin</surname><given-names>R</given-names></name><name><surname>Magee</surname><given-names>S</given-names></name></person-group><article-title>Long-term analysis of pigmentary dispersion syndrome and pigmentary glaucoma.</article-title><source>Ophthalmology</source><year>1986</year><volume>93</volume><fpage>1528</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">3808615</pub-id></citation></ref><ref id="r26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richter</surname><given-names>CU</given-names></name><name><surname>Richardson</surname><given-names>TM</given-names></name><name><surname>Grant</surname><given-names>WM</given-names></name></person-group><article-title>Pigmentary dispersion syndrome and pigmentary glaucoma. A prospective study of the natural history.</article-title><source>Arch Ophthalmol</source><year>1986</year><volume>104</volume><fpage>211</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">3947295</pub-id></citation></ref><ref id="r27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Farrar</surname><given-names>SM</given-names></name><name><surname>Shields</surname><given-names>MB</given-names></name><name><surname>Miller</surname><given-names>KN</given-names></name><name><surname>Stoup</surname><given-names>CM</given-names></name></person-group><article-title>Risk factors for the development and severity of glaucoma in the pigment dispersion syndrome.</article-title><source>Am J Ophthalmol</source><year>1989</year><volume>108</volume><fpage>223</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">2774030</pub-id></citation></ref><ref id="r28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ritch</surname><given-names>R</given-names></name><name><surname>Steinberger</surname><given-names>D</given-names></name><name><surname>Liebmann</surname><given-names>JM</given-names></name></person-group><article-title>Prevalence of pigment dispersion syndrome in a population undergoing glaucoma screening.</article-title><source>Am J Ophthalmol</source><year>1993</year><volume>115</volume><fpage>707</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">8506904</pub-id></citation></ref><ref id="r29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Siddiqui</surname><given-names>Y</given-names></name><name><surname>Ten Hulzen</surname><given-names>RD</given-names></name><name><surname>Cameron</surname><given-names>JD</given-names></name><name><surname>Hodge</surname><given-names>DO</given-names></name><name><surname>Johnson</surname><given-names>DH</given-names></name></person-group><article-title>What is the risk of developing pigmentary glaucoma from pigment dispersion syndrome?</article-title><source>Am J Ophthalmol</source><year>2003</year><volume>135</volume><fpage>794</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12788118</pub-id></citation></ref><ref id="r30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>JS</given-names></name><name><surname>Pralea</surname><given-names>AM</given-names></name><name><surname>del Bono</surname><given-names>EA</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Gorin</surname><given-names>MB</given-names></name><name><surname>Schuman</surname><given-names>JS</given-names></name><name><surname>Mattox</surname><given-names>CG</given-names></name><name><surname>Wiggs</surname><given-names>JL</given-names></name></person-group><article-title>A gene responsible for the pigment dispersion syndrome maps to 7q35-q36.</article-title><source>Arch Ophthalmol</source><year>1997</year><volume>115</volume><fpage>384</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9076212</pub-id></citation></ref><ref id="r31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paglinauan</surname><given-names>C</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>del Bono</surname><given-names>EA</given-names></name><name><surname>Schuman</surname><given-names>JS</given-names></name><name><surname>Stawski</surname><given-names>S</given-names></name><name><surname>Wiggs</surname><given-names>JL</given-names></name></person-group><article-title>Exclusion of chromosome 1q21-q31 from linkage to three pedigrees affected by the pigment-dispersion syndrome.</article-title><source>Am J Hum Genet</source><year>1995</year><volume>56</volume><fpage>1240</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">7726183</pub-id></citation></ref><ref id="r32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wiggs</surname><given-names>JL</given-names></name><name><surname>del Bono</surname><given-names>EA</given-names></name><name><surname>Schuman</surname><given-names>JS</given-names></name><name><surname>Hutchinson</surname><given-names>BT</given-names></name><name><surname>Walton</surname><given-names>DS</given-names></name></person-group><article-title>Clinical features of five pedigrees genetically linked to the juvenile glaucoma locus on chromosome 1q21-q31.</article-title><source>Ophthalmology</source><year>1995</year><volume>102</volume><fpage>1782</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9098278</pub-id></citation></ref><ref id="r33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ritch</surname><given-names>R</given-names></name><name><surname>Mudumbai</surname><given-names>R</given-names></name><name><surname>Liebmann</surname><given-names>JM</given-names></name></person-group><article-title>Combined exfoliation and pigment dispersion: Paradigm of an overlap syndrome.</article-title><source>Ophthalmology</source><year>2000</year><volume>107</volume><fpage>1004</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10811097</pub-id></citation></ref><ref id="r34"><label>34</label><citation citation-type="book">Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor Press; 1989. p. 17&#x02013;19.</citation></ref><ref id="r35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Maller</surname><given-names>J</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name></person-group><article-title>Haploview: analysis and visualization of LD and haplotype maps.</article-title><source>Bioinformatics</source><year>2005</year><volume>21</volume><fpage>263</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15297300</pub-id></citation></ref><ref id="r36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wiggs</surname><given-names>JL</given-names></name></person-group><article-title>Association between LOXL1 and pseudoexfoliation.</article-title><source>Arch Ophthalmol</source><year>2008</year><volume>126</volume><fpage>420</fpage><lpage>1</lpage><pub-id pub-id-type="pmid">18332326</pub-id></citation></ref><ref id="r37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>RK</given-names></name></person-group><article-title>The molecular pathophysiology of pseudoexfoliation glaucoma.</article-title><source>Curr Opin Ophthalmol</source><year>2008</year><volume>19</volume><fpage>95</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">18301281</pub-id></citation></ref><ref id="r38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><collab>Layden We</collab></person-group><article-title>Ritch R, King DG, Teekhasaenee C. Combined exfoliation and pigment dispersion syndrome.</article-title><source>Am J Ophthalmol</source><year>1990</year><volume>109</volume><fpage>530</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">2333916</pub-id></citation></ref></ref-list></back></article> 